hydralazine has been researched along with ANCA-Associated Vasculitides in 16 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 52-year-old Hispanic woman with a medical history of resistant hypertension treated with hydralazine 10 mg twice daily for 1 year presented with generalized weakness, dizziness, nausea, vomiting, and gross hematuria." | 8.31 | Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine. ( Agaronov, A; Akhondi, H; Bhatnagar, M; Pepito, D; Sarkisyan, E; Sotoudeh Deilamy, I, 2023) |
| "Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmune disease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN)." | 8.02 | Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. ( Appel, GB; Batal, I; Bomback, AS; Canetta, PA; D'Agati, VD; Kudose, S; Markowitz, GS; Radhakrishnan, J; Santoriello, D; Stokes, MB, 2021) |
| "Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure." | 7.96 | Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. ( Al-Abdouh, A; Bekele, A; Garcia, P; Seid, H; Siyal, AM, 2020) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 7.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "Hydralazine-induced lupus was first described in 1953." | 5.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| "Hydralazine, an arterial vasodilator, is a widely used medication for the management of hypertension and heart failure, especially for patients who cannot tolerate the use of ACEIs or ARBs." | 5.12 | Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review. ( Al-Sadawi, M; Battisha, A; Doughem, K; Konduru, L; Madoukh, B; Shaikh, S; Sheikh, O, 2021) |
| " We present a patient with hydralazine-induced antineutrophil cytoplasmic antibodies-positive vasculitis with a pulmonary-renal syndrome manifesting as pauci-immune glomerulonephritis and alveolar haemorrhage." | 4.31 | Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis. ( Acharya, I; Arend, LJ; Smith, LW; Weisman, DS, 2023) |
| "A 52-year-old Hispanic woman with a medical history of resistant hypertension treated with hydralazine 10 mg twice daily for 1 year presented with generalized weakness, dizziness, nausea, vomiting, and gross hematuria." | 4.31 | Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine. ( Agaronov, A; Akhondi, H; Bhatnagar, M; Pepito, D; Sarkisyan, E; Sotoudeh Deilamy, I, 2023) |
| "Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmune disease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN)." | 4.02 | Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. ( Appel, GB; Batal, I; Bomback, AS; Canetta, PA; D'Agati, VD; Kudose, S; Markowitz, GS; Radhakrishnan, J; Santoriello, D; Stokes, MB, 2021) |
| "Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure." | 3.96 | Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. ( Al-Abdouh, A; Bekele, A; Garcia, P; Seid, H; Siyal, AM, 2020) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 3.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "Hydralazine is a common arterial vasodilator used in the management of congestive heart failure and hypertension." | 1.62 | Severe cutaneous presentation of hydralazine-induced ANCA vasculitis without renal or pulmonary involvement, complicated by DIC. ( Avelino, ARM; Huo, MX; Singh, G, 2021) |
| "Hydralazine-induced lupus was first described in 1953." | 1.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| "Hydralazine is a commonly used drug for treatment of hypertension and is known to cause drug-induced lupus erythematosus." | 1.38 | Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation. ( Kaw, D; Malhotra, D; Marina, VP, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 9 (56.25) | 2.80 |
| Authors | Studies |
|---|---|
| Acharya, I | 1 |
| Weisman, DS | 1 |
| Smith, LW | 1 |
| Arend, LJ | 1 |
| Bhatnagar, M | 1 |
| Agaronov, A | 1 |
| Sarkisyan, E | 1 |
| Sotoudeh Deilamy, I | 1 |
| Pepito, D | 1 |
| Akhondi, H | 1 |
| Schrom, KP | 1 |
| Field, HE | 1 |
| Chang, T | 1 |
| Montanez-Wiscovich, ME | 1 |
| Al-Abdouh, A | 1 |
| Siyal, AM | 1 |
| Seid, H | 1 |
| Bekele, A | 1 |
| Garcia, P | 1 |
| Doughem, K | 1 |
| Battisha, A | 1 |
| Sheikh, O | 1 |
| Konduru, L | 1 |
| Madoukh, B | 1 |
| Al-Sadawi, M | 1 |
| Shaikh, S | 1 |
| DiLorenzo, AM | 1 |
| Pasieka, HB | 1 |
| Cardis, MA | 1 |
| Santoriello, D | 1 |
| Bomback, AS | 2 |
| Kudose, S | 1 |
| Batal, I | 1 |
| Stokes, MB | 1 |
| Canetta, PA | 1 |
| Radhakrishnan, J | 1 |
| Appel, GB | 1 |
| D'Agati, VD | 1 |
| Markowitz, GS | 1 |
| Huo, MX | 1 |
| Avelino, ARM | 1 |
| Singh, G | 1 |
| Tu, W | 1 |
| Fayman, B | 1 |
| Ward, SC | 1 |
| Mamoon, Y | 1 |
| Bandagi, SS | 1 |
| Aeddula, NR | 1 |
| Pathireddy, S | 1 |
| Ansari, A | 1 |
| Juran, PJ | 1 |
| Pendergraft, WF | 1 |
| Niles, JL | 1 |
| Suneja, M | 1 |
| Baiswar, S | 1 |
| Vogelgesang, SA | 1 |
| Magro, CM | 1 |
| Momtahen, S | 1 |
| Harp, J | 1 |
| Sangala, N | 1 |
| Lee, RW | 1 |
| Horsfield, C | 1 |
| Goldsmith, DJ | 1 |
| Marina, VP | 1 |
| Malhotra, D | 1 |
| Kaw, D | 1 |
2 reviews available for hydralazine and ANCA-Associated Vasculitides
| Article | Year |
|---|---|
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis; Heart | 2021 |
Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cocaine; Cocaine-Related Disorders; Drug | 2014 |
14 other studies available for hydralazine and ANCA-Associated Vasculitides
| Article | Year |
|---|---|
Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Antineutrophil cytoplasmic antibody vasculitis induced by hydralazine.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensive Agents; Female; H | 2020 |
Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis; Hemorrhage; | 2020 |
An Edematous and Ulcerative Eruption With Nasolabial Sparing in an Older Woman.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensive Agents; Biopsy; B | 2020 |
Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2021 |
Severe cutaneous presentation of hydralazine-induced ANCA vasculitis without renal or pulmonary involvement, complicated by DIC.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2021 |
Hydralazine-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Asymptomatic and Renal-Restricted Presentation.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2021 |
Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biopsy; Blood Protein Electrophore | 2018 |
Hydralazine associated pauci-immune glomerulonephritis.
Topics: Aged; Aged, 80 and over; Amlodipine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Ant | 2014 |
The distinctive histopathology of hydralazine-associated ANCA positive vasculitis: in vivo demonstration of NETosis.
Topics: Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensiv | 2017 |
An Elderly Man with Fatigue, Dyspnea, and Kidney Failure.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2017 |
Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensive Agents; Female; Humans; | 2010 |
Hydralazine-induced ANCA vasculitis with pulmonary renal syndrome: a rare clinical presentation.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antihypertensive Agents; Glomerulonephri | 2012 |